NextCell Pharma

The article, published by GEN - one of the top-ranked biotechnology industry publications, with a global readership of over 870,000 - recognises NextCell as part of FUJIFILM's strategic transformation. The collaboration provides an integrated solution for researchers and developers in the cell therapy field, combining:

• NextCell's umbilical cord-derived MSC product (research-use-only)
• FUJIFILM's PRIME XV MSC culture media
• Cryopreservation solutions

"Being featured in FUJIFILM's broader strategic communication reinforces the significance of our collaboration," said Mathias Svahn, CEO of NextCell. "It highlights our shared commitment to advancing cell therapy technologies through standardisation and scalability."

GEN's editorial coverage spans the full bioproduct life cycle, from early-stage research to commercialisation, and is followed by leading scientists, executives, and investors in the global biotech sector. Approximately 75% of its readership is based in the United States and 18% in Europe.

Recognition by GEN further underscores the growing importance of NextCell's MSC platform within regenerative medicine and the next generation of biomanufacturing.

Read the full article here:
End-to-End: Fujifilm Rebrands Life Sciences Companies - GEN, 8 July 2025